Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Avemar is a biotechnology company centered on the production and scientific validation of its flagship product, a patented fermented wheat germ extract (FWGE). Developed in Hungary, the company's primary offering is utilized globally as a medical food and dietary supplement for cancer patients to support standard oncological treatments. The extract works by inhibiting enzymes involved in the pentose phosphate pathway and modulating the immune system's response to malignant cells. Avemar's research portfolio includes numerous clinical studies across various indications, including colorectal, breast, and lung cancers, as well as autoimmune conditions like rheumatoid arthritis. The company maintains a strong focus on scientific validation, with numerous peer-reviewed publications supporting its mechanism of action and clinical benefits. The product was inspired by the research of Nobel Prize winner Albert Szent-Györgyi and is manufactured under strict GMP standards.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Avemar.